Summary
WHEN Protherics was formed back in 1999, following the merger of two laggards of the biotech sector, Proteus International and Therapeutic Antibodies, one City hack uncharitably dubbed the union 'a merger of the weaklings'.
Things have moved on since then. The firm is now one of the strongest-quoted fledgling drugs developers, with two products on the market, a potential blockbuster in the clinic and more than enough cash in the bank to fund its current research programme.See the full content of this document
Extract
Protherics Safe Bet in a Slippery Sector
Yet over the past year the shares have tumbled by a third. Since hitting a peak of 95p back in 2006 they have lost 60pc of their value.
This is odd, really for while th...See the full content of this document
Sponsored links
